← Leaderboards
Gregory David
New York University School Of Medicine
$4,111,966
Attributed
$4,111,966
Total exposure
6
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $822.4K · FY2011–24$1M$750K$500K$250K$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$4,111,966 · 6
By mechanism
R01$2,004,943 · 1
R21$1,398,905 · 3
R56$538,618 · 1
R03$169,500 · 1
Top collaborators
No co-investigators on record.
Most similar at New York University School Of Medicine
Same institution · by research overlap
- Iannis Aifantis$31,581,069
- Alexander Calderon$148,972
- Joseph Nicholas Pucella$176,194
- Eva Hernando$15,270,218
- Elizabeth H Nardin$7,927,613
Others in their field
Top investigators on “Cells”
- Lawrence Corey · Fred Hutchinson Cancer Center$536,344,731
- Barton F Haynes · Duke University$457,457,619
- David Heimbrook · Leidos Biomedical Research, Inc.$454,789,509
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$299,104,942
- Dennis R. Burton · Scripps Research Institute$278,781,854
- Mary M Horowitz · Medical College Of Wisconsin$237,383,608
Research focus
CellsCell CycleMolecularStressTumor ProgressionSenescenceMalignant NeoplasmsTumorMouse ModelPreventPathway InteractionsMediatingIn VivoSignal TransductionGeneticPhenotypeCell AgingBiologicalProgramsGenesLinkExhibitsLesionMalignant Neoplasm Of Pancreas
Grant awards (15)
Targeting the HMGB1-TLR5 pathway to prevent senescence-induced metastasis in breast cancer.$84,750
R03 · FY2024 · CA · contact PI
Targeting the HMGB1-TLR5 pathway to prevent senescence-induced metastasis in breast cancer.$84,750
R03 · FY2023 · CA · contact PI
Probing the coordination of cell cycle progression and differentiation in hematopoietic stem cells$538,618
R56 · FY2022 · HL · contact PI
Targeting the senescence-associated secretory phenotype as an adjuvant therapy to prevent breast cancer progression$435,827
R21 · FY2020 · CA · contact PI
(PQ1) Cellular senescence as an initiating event in malignant transformation$169,500
R21 · FY2018 · CA · contact PI
(PQ1) Cellular senescence as an initiating event in malignant transformation$203,400
R21 · FY2017 · CA · contact PI
Regulation of Cellular Senescence and Oncogenic Transformation by Sin3B.$350,675
R01 · FY2015 · CA · contact PI
Regulation of Cellular Senescence and Oncogenic Transformation by Sin3B.$340,155
R01 · FY2014 · CA · contact PI
Regulation of Cellular Senescence and Oncogenic Transformation by Sin3B.$283,128
R01 · FY2014 · CA · contact PI
Role of cell cycle withdrawal in restricting pancreatic cancer progression.$199,078
R21 · FY2014 · CA · contact PI
Regulation of Cellular Senescence and Oncogenic Transformation by Sin3B.$329,635
R01 · FY2013 · CA · contact PI
Role of cell cycle withdrawal in restricting pancreatic cancer progression.$207,312
R21 · FY2013 · CA · contact PI
Regulation of Cellular Senescence and Oncogenic Transformation by Sin3B.$350,675
R01 · FY2012 · CA · contact PI
Role of cell cycle withdrawal in restricting pancreatic cancer progression.$183,788
R21 · FY2012 · CA · contact PI
Regulation of Cellular Senescence and Oncogenic Transformation by Sin3B.$350,675
R01 · FY2011 · CA · contact PI